-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$56.86-2.35% Downside
Halozyme Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Piper Sandler, Wells Fargo, Goldman Sachs, Leerink Partners, Morgan Stanley in the past 90 days.